Skip to main content

Hepatitis

Volume 482: debated on Tuesday 11 November 2008

To ask the Secretary of State for Health pursuant to the answer of 6 October 2008, Official Report, columns 424-5W, on hepatitis, how many drugs were dispensed for the treatment of hepatitis B in each strategic health authority area in each year since 1997, broken down by type of drug. (231966)

The following three tables show the number of prescription items dispensed in the community for the treatment of hepatitis B. The information is provided according to the individual British National Formulary (BNF) categories hepatitis B drugs fall within. Figures are split by strategic health authority (SHA) and presented in thousands. The data do not cover drugs dispensed in hospitals, including mental health trusts, or private prescriptions.

Due to the disclosive nature of the data, it was not possible to present the data by type of drug. As such, data were aggregated to BNF category to maintain some measure of difference between drug type.

BNF paragraph 8.2.4—Other immunomodulating drugs

Number of prescription items used in the treatment of hepatitis B from BNF section 8.2.4, which were dispensed in the community in England from July 2003 to June 20081

Thousand

SHA2,3

Jul-Dec 2003

2004

2005

2006

2007

Jan-Jun 2008

East Midlands

0.1

0.1

0.1

0.1

0.1

4

East of England

0.1

0.2

0.2

0.1

0.1

4

London

0.1

0.2

0.2

0.2

0.2

0.1

North East

4

4

4

4

4

4

North West

0.2

0.2

0.3

0.2

0.2

0.1

South Central

0.1

0.1

0.2

0.1

0.1

4

South East Coast

0.2

0.3

0.2

0.1

0.1

0.1

South West

0.1

0.1

0.2

0.1

0.2

0.1

West Midlands

0.2

0.3

0.3

0.2

0.2

0.1

Yorkshire and the Humber

4

0.1

0.1

0.1

0.1

4

England

1.0

1.7

1.7

1.3

1.3

0.6

1 Information at SHA level is only available for the past 60 months.

2 The data have been structured in line with current SHA arrangements. The structure changed during 2006 where the number of SHA reduced.

3 The tables show drugs which may be used to treat hepatitis B, by SHA.

4 Indicates 50 or fewer items were dispensed during the period

Source:

The Prescription Pricing Division of the NHS Business Services Authority (NHSBSA (PPD))

BNF paragraph 5.3.3—Viral hepatitis

Number of prescription items used in the treatment of hepatitis B from BNF section 5.3.3, which were dispensed in the community in England from July 2003 to June 20081

Thousand

SHA2,3

Jul-Dec 2003

2004

2005

2006

2007

Jan-Jun 2008

East Midlands

4

4

4

4

0.1

0.1

East of England

4

4

0.1

4

0.1

0.1

London

0.1

0.1

0.2

0.5

0.6

0.3

North East

4

4

4

4

4

4

North West

4

4

4

4

0.1

0.1

South Central

4

4

4

4

0.1

0.1

South East Coast

4

4

0.1

0.1

0.1

0.1

South West

4

4

4

0.1

0.1

0.1

West Midlands

4

4

4

4

0.1

0.1

Yorkshire and the Humber

4

4

4

4

0.1

0.1

England

0.1

0.3

0.5

0.9

1.5

1.0

1 Information at SHA level is only available for the past 60 months.

2 The data have been structured in line with current SHA arrangements. The structure changed during 2006 where the number of SHA reduced.

3 The tables show drugs which may be used to treat hepatitis B, by SHA.

4 Indicates 50 or fewer items were dispensed during the period

Source:

The Prescription Pricing Division of the NHS Business Services Authority (NHSBSA (PPD))

BNF paragraph 5.3.1-HIV infection

Number of prescription items used in the treatment of hepatitis B from BNF section 5.3.1, which were dispensed in the community in England from July 2003 to June 20081

Thousand

SHA2,3

Jul-Dec 2003

2004

2005

2006

2007

Jan-Jun 2008

East Midlands

0.1

0.2

0.2

0.3

0.4

0.2

East of England

0.2

0.4

0.5

0.6

0.8

0.4

London

0.7

1.7

1.9

2.4

3

1.6

North East

0.1

0.2

0.2

0.3

0.2

0.1

North West

0.3

0.5

0.5

0.6

0.7

0.4

South Central

0.1

0.2

0.2

0.3

0.3

0.2

South East Coast

0.1

0.2

0.3

0.4

0.4

0.2

South West

0.1

0.2

0.3

0.4

0.4

0.2

West Midlands

0.3

0.6

0.6

0.7

0.7

0.4

Yorkshire and the Humber

0.1

0.3

0.3

0.4

0.5

0.3

England

2.0

4.5

5.1

6.4

7.4

4.0

1 Information at SHA level is only available for the past 60 months.

2 The data have been structured in line with current SHA arrangements. The structure changed during 2006 where the number of SHA reduced.

3 The tables show drugs which may be used to treat hepatitis B, by SHA.

4 Indicates 50 or fewer items were dispensed during the period

Source:

The Prescription Pricing Division of the NHS Business Services Authority (NHSBSA (PPD))

The following product list was identified for use in the treatment of hepatitis B. It includes specific brands licensed for the treatment of hepatitis B and drugs that may also be licensed for use in other indications. BNF 55, NHS Choices Map of Medicine and NICE Technology Appraisal 96 have been used to identify the products. The data provided have been aggregated from the following specific brands to the respective BNF category as indicated. It does not include those products used for the prevention of hepatitis B.

BNF Paragraph 8.2.4: Other immunomodulating drugs; includes the products IntronA, Pegasys, Roferon-A and Viraferon. These drugs can also be used in other indications. Other products in this BNF chapter not used in the treatment of hepatitis B have been excluded.

BNF Paragraph 5.3.3: Viral hepatitis; includes the products Baraclude, Hepsera and Sebivo. These drugs are only indicated for use with hepatitis B.

BNF Category 5.3.1: HIV infection; includes the products Viread and Zeffix. These drugs can also be used in other indications. Other products in this BNF chapter not used in the treatment of hepatitis B have been excluded.